Can a GAGome score predict who will develop cancer over the next five years, among people who currently have none? LEVANTIS-0087A (LEV87A) is a retrospective population cohort-based nested case-control study in adults aged 35–80, asymptomatic at sampling with with no recent history of cancer.
Can a plasma GAGome test find cancers that CT screening alone would miss — and can it help decide who is scanned? LEVANTIS-0093A (LEV93A) is a prospective observational cohort study in 55 to 80 years old adults with significant smoking history.
Can a GAGome score identify which firefighters will develop cancer in the next five years? LEVANTIS-0065 (LEV65) is a retrospective observational cohort study in actively working firefighters, using plasma and urine collected in the VCC-MCEDFF-001 study at Vincere Cancer Center, Scottsdale, Arizona
(Completed) AURORAX-0087A (AUR87A) was a prospective multi-center observational cohort study to validate the performance of the urine free GAGome RCC test for the early detection of recurrence after curative intent surgery in patients with high or intermediate risk clear cell renal cell carcinoma.
Can liquid biopsy replace invasive surveillance for people with an inherited cancer predisposition? PREDI-LYNCH aims to develop and validate non-invasive, accurate, and cost-effective liquid biopsy tests to detect cancer at its earliest stages in Lynch Syndrome carriers.
AURORAX-0093A (AUR93A) is a prospective observational cohort study to develop free GAGome-based tests for the prognosis of muscle-invasive bladder cancer patients elected for neo-adjuvant chemotherapy before radical cystectomy.
This study aims to collect urine samples from healthy people to understand the best conditions for Elypta's test regarding how urine samples are taken, processed, and stored.
.svg)
